CTOs on the Move

Grady Memorial Hospital

www.gradymem.org

 
Grady Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Grady Memorial Hospital is based in Chickasha, OK. You can find more information on Grady Memorial Hospital at www.gradymem.org
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Primus Pharmaceuticals

Primus Pharmaceuticals, Inc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Primus Pharmaceuticals, Inc is based in Scottsdale, AZ. You can find more information on Primus Pharmaceuticals, Inc at www.primusrx.com

Rodeo Dental and Orthodontics

Rodeo Dental & Orthodontics is transforming the world of dentistry into a bright, fun-filled, high-end experience. How? By combining beautiful smiles, world-class service, and magical patient engagement techniques into memorable experiences that are shared instantly with family and friends!

Accent On Health

Accent On Health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Martin-Deneen Associates Inc

Martin-Deneen Associates Inc is a Grass Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.